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ABSTRACT: N-acetyl-L-cysteine (NAC) is a well-known antioxidant that is capable of facilitating glutathione (GSH) biosyntbesis
and replenishing intracellular GSH under oxidalively challenging circumstances. N-acetyl-cysteine-amide (NACA), the amide
form of NAC, is a newly designed and synthesized thiol-containing compound which is believed to be more lipophilic and perme-
able through cell membranes than NAC. The metabotc and antioxidant effects of these compounds tx vito atjLd in vivo are under
investigation. However, an analytical method that can separate and quantify both compounds simultaneously is not yet available,
to the best of our knowledge. Because of their structual similarities, the two compounds are difficult to separate using earlier
IIPLC methods which were designed for NAC quantification. Therefore, the goal of this work was to develop an HPLC method
with fluorescence detection for simultaneous quantification of NAC and NACA in biological blood and tissue samples. A gradient
[{PLC program with fluorescence detection (1* = 330 nrn, i.. = 376 nm) using N-(1-pyrenyl)maleimide (NPM) as the derivatizing
agent was developed. The calibration curves were linear over a concentration mnge of 25-5000 nM (r': > 0,97). The coefficients of
variation for within-run precision and between-run precision ranged from 0.67 to 5.23"/" and for accuracy ranged ftom 0.98 to
10.54%; the percentage relative recovery ranged from 94.5 to 1@.8%. This new method provides satisfactory separation of NAC
and NACA, along with other biological thiols, in 20 min with a 5 nM limit of detection (LOD) per 5 [L injection volume. Copy-
dght @ 2005 John wiley & sons, Ltd.
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INTRODUCTION
N-acetyl-L-cysteine (NAC) is a well-known thiol-
containing antioxidant that has been used in the clinics
for multiple uses for more than 50 years (Kelly,
1998; Holdiness, I99I: Parcell, 20A2: Ziment, 1986;
Flanagan, 1987), and it is the only approved antidote
for acetaminophen intoxication. The evidence from
both in vitro and in yivo studies indicates that NAC
is capable of facilitating intracellular glutathione
(GSH) biosynthesis by reducing extracellular cystine to
cysteine (lssels et al., 1988), or by supplying sulfhydryl
(-SH) groups that can stimulate GSH synthesis and
enhance gluathione-S-transferase activity (Nakata et al.,
1996; De Vries and De Flora, 1993; De Flora et al.,
1985). NAC is also a potent free radical scavenger as a
*Correspondence to: N. Ercal, Department of Chemistry, University
of Missouri-Rolla, 1870 Miner Circle. Rolla. MO 65409, USA.
E-mail: nercal@umr.edu
Abbreviations used: CYS, cysteine; GSH, glutathione; HCYS,
homocysteine; NAC. N-acetyl-l-cysteine; NACA, N-acetyl-l-cysteine
amide; NPM, N-(1 -pyrenyl)maleimide.
Contract/grant sponsor: NIEHS; Contract/grant number:
1R15ESO12167-01A1_
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result of its nucleophilic actions on reactive oxygen
species (Aruoma et al., 1989). Therefore, NAC treat-
ment or supplementation can be considered for condi-
tions of GSH depletion and free radical formations
during oxidative stress. NAC has also been used as a
metal chelating agent for several toxic metals such as
boron, chromium, cobalt, cadmium, arsenic, gold and
lead (Barnner et al., 1986; Llobet et al., 1986; Patrick,
2003: Ottenwalder and Simon, 1987). Some studies
have also demonstrated that NAC can act as a radio-
protective agent against much oxidative damage in-
duced by UV, ionizing radiation, and gamma rays (Neal
et al., 2003; Murley et al., 2004: Morley et al., 2003;
Sridharan and Shyamaladevi, 2002; Pajonk et a1.,2002).
l/-acetyl-cysteine-amide (NACA), the amide form
of NAC, is a newly designed and synthesized thiol-
containing compound. NACA is believed to cross the
cell membrane more easily due to its high lipophilicity.
One recent study provided evidence that NACA had
more efficient membrane permeation than NAC and
could replenish intracellular GSH in red blood cells
(Grinberg et aL.,2005). This compound was also shown
to cross the blood-brain barrier, scavenge free-radicals,
chelate copper, and protect red blood cells from






















Figure L. Structures of NAC and NACA.
The metabolic and antioxidant effects of these com-
pounds ln vitro and in vivo are under investigation.
However, an analytical method that can simultaneously
separate and quantify both compounds along with
other biological thiols, such as glutathione, cysteine
(CYS) and homocysteine (HCYS), is not yet available,
to the best of our knowledge. Because of the structural
similarities between these two compounds (Fig. 1), they
are difficult to separate using earlier HPLC methods
that were designed for NAC quantification in biological
samples (Winters et a\.,1995; Ercal et a\.,7996; Baeyens
et aL.,1988; Cotgreave and Moldeus, 1987).
N-(1-pyrenyl)maleimide (NPM) is an aromatic com-
pound that can selectively react with sulfhydryl groups
and form a fluorescent adduct with a high extinction
coefficient (Fig. 2). It has been used by our research
group as the fluorescent derivatizing agent for many
thiol compounds (Winters et al., 1995; Ercal et a!., 1996;
W. Wu el a/.
Yusof er al., 2000). The goal of this study was to
develop an HPLC method for the separation and
simultaneous quantification of NAC and NACA with
fluorescence detection using NPM as the derivatizing
agent. Biological thiols, such as glutathione, cysteine
and homocysteine, can also be determined simultane-
ously using this method.
EXPERIMENTAL
Reagents and chemicals. Acetonitrile, acetic acid and
o-phosphoric acid (all HPLC grade) were purchased from
Fisher Scientific (Houston, TX, USA). NAC, GSH, CYS,
HCYS and NPM were purchased from Sigma (St Louis, MO,
USA). NACA was provided by Novia Pharmaceuticals Ltd
(Haifa Bay, Israel).
Animals. All experiments were performed with adult
Sprague-Dawley rats, each weighing about 250 g, that were
purchased from Charles River Laboratories (Wilmington,
MA, USA). They were kept in a temperature-controlled
(25"C) room equipped to maintain a 12 h light-dark cycle.
Standard rat chow (Purina rat chow) and tap-water were
given ad libitum. NACA 500 mgikg body weight was orally
administrated to the rats after overnight fasting. Thirty
minutes later after dosing, rats were anesthetized and
sacrificed according to the University of Missouri Animal
Care Regulations. Plasma and tissue samples were collected
and then kept at -70"C for later analysis, or minced and
homogenized on ice and derivatized by NPM immediately.
HPLC system. The I{PLC system (Thermo Electron
Corporation) consisted of a FinniganrM SpectraSYSTEM
SCM1000 Vacuum Membrane Degasser, a FinniganrM
SpectraSYSTEM P2000 Gradient Pump, a FinniganrM
SpectraSYSTEM AS3000 autosampler and a FinniganrM
SpectraSYSTEM FL3000 fluorescence detector (L. : 330 nm
and 1,"- = 376 nm). The injection volume was 5 pL for all the
plasma and tissue samples. The HPLC column was a Reliasil
ODS-1 C,, column (5 pm packing material) with 250 x
4.6 mm i.d. (Column Engineering, Ontario, CA, USA). Two
HsH2,
HS- R
NPM thiol NPM-thiol adduct
Figure 2. Formation of fluorescent NPM-thiol adduct.
Sons, Ltd. Biomed. Chromatogr.20: 415-422 (2006)
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Separation and quantification of NAC and NACA
Table 1. Gradient program of mobile phases used in the
separation
, l
I  l i l
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used to normalize the thiol concentration data, so that a
reasonable comparison could be achieved between different
treatment groups. The Coomassie blue dye working solution
was made by diluting concentrated Coomassie blue solution
(Bio-Rad Laboratories, Hercules, CA, USA) with distilled
water (1.:4, vlv). A standard curve was constructed using
0.05 mL bovine serum albumin (BSA), ranging from 0.25 to
1.0 mg/ml, as the serial standard solutions with the addition
of 2.5 mL of the Coomassie blue working solution. The homo-
genated tissue samples were subjected to appropriate dilu-
tions and 0.05 mL of each sample was added to 2.5 mL of the
same Coommasie blue working solution that had been used
in the standard curve construction. The mixtures were then
incubated at room temperature for at least 5 min and the
absorbance was measured at 595 nm by a spectrophotometer.
METHOD VALIDATION
Calibration curves
Calibration curves (Fig. 3) were plotted using inte-
grated peak areas vs standard thiol concentrations (25,
125, 500, t250, 2500 and 5000 nrr,r). Linearity in each
curve was achieved over a concentration ranqe of 25-
5000 niu (r2 > 0.997).
Accuracy, precision and recovery
Accuracy was determined by analyzing seven replicates
of plasma or tissue samples containing25,125, 500 and
1250 nu of NAC and NACA, respectively. The mean
values for the seven replicates at each concentration in
each matrix were calculated and the relative deviation
of mean value from the true value served as the meas-
ure of accuracy.
Within-run precision was determined by analyzing
seven replicate NAC- or NACA-spiked control plasma
samples or tissue samples at concentration levels rang-
ing from 25 to 1250 nu in one analytical run, and com-
paring the NAC or NACA concentrations calculated
from the peak areas of the seven replicates in each
matrix. [The average calibration curves used in the
calculations were, for NAC, | = 30.857x - 1626.5 (r' -
0.999); for NACA, y - 29.331x + 437.36 (r' - 0.999)1.
Between-run precision was obtained by derivatizing
seven replicate NAC- or NACA-spiked control plasma
samples or tissue samples at concentration levels rang-
ing from 25 to 1250 nu in three different analytical runs
and comparing the NAC or NACA concentrations
calculated from the peak areas of the seven replicates
in each matrix. The coefficients of variations were
calculated in each matrix and served as the measure of
precision.
Relative recovery was determined by spiking the
liver, kidney, lung, brain and plasma samples with 25,


























Mobile phase A: 0.05% acetic acid in 70:30 acetonit i l le-HPlc-H2o
(v:v) .
Mobile phase B: 0.47" o-phosphoric acid in 70:30 acetonitrile-
HPLC-HrO (v:v).
mobile phases were used in the gradient separation program:
mobile phase A was composed of 0.05% acetic acid in 70:30
acetonitrile-HPlc-HrO (v:v) and mobile phase B was com-
posed of 0.4"/" o-phosphoric acid in 70:30 acetonitrile-HPlc-
HrO (v:v). The gradient program (Table 1) was used for
optimal separation and quantification of NAC. NACA and
other biological thiols.
Preparation of calibration solution. For calibration studies,
a calibration standard stock solution of NAC and NACA
(1 mu) was prepared by accurately weighing out 0.0016 g
of both NACA and NAC and dissolving them to 10 mL of
serine-borate buffer (100 mu Tris buffer containing 10 mvr
borate and 5 mu serine with 1 mu diethylenetriamine-
pentaacetic acid; pH = 7.0; Neal et al.. 1991). This stock
mixture solution was further diluted in serine-borate buffer to
prepare the diluted calibration standard working solutions
(100 and 10 pu). Varying volumes of these working solutions
were added into plasma or tissue homogenates and to pre-
pare the final plasma or tissue calibration standard solutions
in varying concentrat ions, as 25,125.250,500. 1250, 2500 and
5fi)0 nu.
Sample preparation and derivatization. Plasma was
obtained by centrifugating blood samples for 10 min at 1000 g.
Tissue samples, ranging from 0.2 to 0.5 g, were minced and
homogenized in 1 mL serine-borate buffer as described
above. L-Serine, in the presence of borate, can inhibit y-
glutamyl transpeptidase (GGT) which exists in some bio-
logical tissues such as the liver and kidneys, and can
hydrolyze GSH; therefore, it is used to prevent the loss of
GSH during the process of homogenization. Two-hundred
and fifty microliters of plasma or tissue homogenates were
added to a 750 pL 1 mu NPM solution and incubated at room
temperature for 5 min: then 10 pL of 2 u HCI were added to
stop the reaction. The final pH of the solution should be less
than 2.0. which is important for stabilizing the derivatives.
Derivatized plasma or tissue samples were filtered through
0.45 pm nylon filters (Advantec MFS Inc., Dulin, CA, USA)
and injected directly onto the HPLC system.
Protein assay. The Bradford method (Bradford, 1976) was
used to determine the protein contents of the tissue samples
and the protein content determined in each tissue sample was
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NAC: Y =28.712x- 1862.6
R2 = 0.997






Ftgure 3. Calibration curves of NAC and NACA in plasma matrix.
Table 2. Between-nm and within-run precision, rccuracy and rchlive recovery of lhree samples spiked wilh NAC and NACA (25,
1115, 500 nrd L250 nM) in ssmpl,e matrices and slandards
Sample matrix Plasma Kidney Lung Brain Liver Standard
Between-run precision (n = 7) 2.06-4.89"/"
Within-run precision (n:7) 1.94-3.58"/0
Accuracy (n = 7) 1.58-6.76"/"








102.8 t 3.3 N/A
Percentage relative recovery is reported as the average relative recovery (tstandard deviation) of the sarnples spiked itith 25, 125, 500 and
1250 nM NAC and NACA in each sample matrix. N/A = not applicable.
replicates. Recoveries were calculated by comparing
the analytical results for those three spiked samples
with the un-spiked pure standards at the above-
mentioned four concentrations that represent the lffi"/"
recovery.
The coefficients of variation (CV) for between-run
and within-run precision, the relative deviation for
accuracy, and relative recovery of the samples spiked
with NAC and NACA (25, 125, 500 and 1250 nu) in
the sample matrix and standards are shown in Table 2.
The CVs for within-run precision and between-run
precision ranged from 0.67 to 5.23% and the relative
deviations for accuracy ranged from 0.98 to 10.54Y";
the percentage relative recovery ranged from 94.5 to
102.8%.
Sensitivity and autosample stabil ity
The lower limit of quantitation (LLOO) was the con-
centration of NAC or NACA when its peak area was
10 times that of the peak area of the blank (signal-
to-noise = 10). The LLOQ of both NAC and NACA
by this method was found to be 25 nnr. The detection
limit determined by this technique was found to be
5 nrr,r (signal-to-noise = 3) with 5 pL injection volume.
The autosample stability was measured by deter-
mining the seven replicates of derivatized NAC- and
Copyright O 2005 John Wiley & Sons, Ltd.
NACA-spiked plasma or tissue samples at three con-
centrations (125, 500 and 1250 nu) kept in HPLC
autosampler vials and stored at room temperature after
0, 6, 12 or 24 h of sample derivatization or stored at
4'C after l, 3, 6 or 12 days of sample derivatization.
The relative standard deviations were found to be less
than 10% when the derivatized samples were stored
at room temperature and less than 15% when the
derivatized samples were stored at 4'C at those varying
concentrations in each sample matrix.
Investigation of interferences
Figure 4 shows a chromatogram of a derivattzed stand-
ard mixture (1250 nrvr) of NAC, NACA, GSH, CYS
and HCYS in a liver matrix with NPM derivatization.
The retention time of NAC was 4.84 min and the re-
tention time of NACA was 5.25 min. As seen in Fig. 4,
the aforementioned biological thiols do not interfere
with the detection of NAC and NACA when this
method is used.
RESU LTS
This study examined the deivatization of NAC and
NACA with NPM and their separation by the gradient
Biomed. Chromatogr. 20: 41.5-422 (2N6)
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Figure 4. Chromatogram of a derivatized standard mixture (1250 nu) of NAC (4.835 min). NACA
(5.250 min). GSH (9.475 min). CYS (10.197 min) and HCYS (10.703 min) in a liver matrix. Separation condi-
tions: an ODS-1 C,, column (5 pm packing material) with 250 x 4.6 mm (i.d.) was used for the separation.
I!:.';xti"J,,"i:x'''1T ;i#"",',*J'#,?,:lii::'j!si,fff ^ T':'#"lfi section rhe NPM derivatives
Table 3. Thiol levels in biological samples after 30 min oral administration of 5ffi mg/kg body weight NACA
Thiol levels (mean + SD)
Samples NAC NACA GSH
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Calibration curves used in the above calculation: GSH, 
-v =10.27Ix +233.39; CYS, y = 10.089-r +253.65.
Unit for plasma samples is ;rvr; unit for tissue samples is nmol/mg protein. ND = not detectable. SD = standard deviation.
HPLC system. Figure 5(a) shows the chromatogram
of a control plasma sample from Sprague-Dawley
rats given phosphate-buffered saline solution only. As
seen in Fig. 5(a), there is no NACA peak in this
chromatogram. Figure 5(b) shows the chromatogram of
the plasma sample obtained from an animal that was
administrated 500 mg/kg body weight of NACA and
sacrificed 30 min thereafter. Both NAC and NACA
peaks appeared right before the NPM hydrolysis peaks.
Figure 6 shows the chromatograms of lung samples ob-
tained from Sprague-Dawley rats. The chromatogram
of a control lung sample (a) shows no peaks at the
Copyright O 2005 John Wiley & Sons, Ltd.
retention times of these two compounds (NAC and
NACA), while the chromatogram of the lung sample
from a rat given NACA (b) had a significant NAC
peak at 4.8 min and a smaller NACA peak at 5.2 min.
The levels of these important biological thiols in
samples of plasma, liver, lung, kidney and brain tissues
are reported in Table 3. The blood and tissue samples
were collected after 30 min oral administration of
500 mgikg body weight NACA. The levels of the thiols
in the tissue samples were calculated by using the thiol
concentrations (tru) of homogenated tissue solutions
over the protein content in the solutions (mg protein/
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Figure 5. Chromatograms of plasma samples obtained from Sprague-Dawley rats. Separation conditions
are the same as those in Fig. 4. (a) Control plasma sample obtained from an animal administrated with
phosphate-buffered saline solution only (no NACA peak). (b) Plasma sample obtained from an animal
sacrificed 30 min after the administration of 5ffi mgikg body weight NACA.
mL). The concentration of NACA in plasma samples
was significant after 30 min oral administration of
500 mg/kg NACA, compared with the levels of NACA
in control samples that had received only phosphate
buffered saline solution. It was also noticed that the
Copyright O 2005 John Wiley & Sons. Ltd.
concentrations of other biological thiols (such as GSH
in the plasma and liver samples and CYS in plasma,
kidney, lung and liver samples) increased after NACA
administration, indicating that NACA can replenish





































Biomed. Chromatogr. 20: 415 -422 (2ffi6)




























A new HPLC method, using NPM as the derivatizing
agent, has been developed for separating and quantify-
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Figure 6. Chromatograms of lung samples obtained from Sprague-Dawley rats. Separation conditions are the
same as those in Fig. 4. (a) Chromatogram of the control lung sample showing no NAC or NACA peaks. (b)














































ing NAC and NACA. High concentrations of biological
thiols (GSH, CYS and HCYS) do not interfere with the
determination of NAC and NACA. The application of
























liver. lung, kidney and brain provided satisfac-
tory results.
This assay provides a sensitive, rapid and simple
method for analyzing NAC, NACA, GSH, CYS and
HCYS simultaneously in biological samples. It is also
a useful tool for studying the metabolic mechanisms
and various effects of NAC and NACA in biolosical
environments.
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